61. 自己免疫性溶血性貧血 Disease details / Clinical trials / Drug dev / DR info
臨床試験数 : 146 / 薬物数 : 131 - (DrugBank : 59) / 標的遺伝子数 : 28 - 標的パスウェイ数 : 158
薬物ごとの開発者（Primary Sponsor）、臨床試験情報（抜粋）です。
ACT-HIB Polvere e solvente per soluzione iniettabile in siringa preriempita 0,5 ml
NOVARTIS PHARMA AG
2022 Phase 2 EUCTR2021-002039-40-IT Germany;Italy;Korea, Democratic People's Republic of;Spain;United Kingdom;United States;
ALXN1830
ALEXION PHARMACEUTICALS INCORPORATED
2021 Phase 2 EUCTR2021-001211-90-IT France;Germany;Italy;Korea, Republic of;Spain;United Kingdom;United States;
Alexion Pharmaceuticals
2022 Phase 2 NCT04956276 United States;
2021 Phase 2 NCT04256148 United States;
2018 Phase 1/Phase 2 NCT03075878 Jordan;United States;
Alexion Pharmaceuticals, Inc.
2021 Phase 2 EUCTR2021-001211-90-ES France;Germany;Italy;Korea, Republic of;Spain;United Kingdom;United States;
2020 Phase 2 EUCTR2019-004055-37-ES Australia;Belgium;Canada;France;Germany;Italy;Korea, Republic of;Netherlands;Russian Federation;Spain;Taiwan;United Kingdom;United States;
ANX005
Annexon, Inc
2020 Phase 2 EUCTR2020-003675-18-IT Austria;France;Germany;Hungary;Italy;Netherlands;Norway;Spain;United Kingdom;
Annexon, Inc.
2021 Phase 2 EUCTR2020-005854-90-AT Austria;
2021 Phase 2 EUCTR2020-003675-18-DE Australia;Austria;Bulgaria;Czechia;France;Germany;Italy;Spain;United Kingdom;United States;
2021 Phase 2 EUCTR2020-003675-18-BG Australia;Austria;Bulgaria;Czechia;France;Germany;Italy;Spain;United States;
2021 Phase 2 EUCTR2020-003675-18-AT Australia;Austria;Bulgaria;Czechia;France;Germany;Italy;Spain;United Kingdom;United States;
APL-2
APELLIS PHARMACEUTCIALS, INC.
2018 Phase 2 EUCTR2017-003363-35-IT Italy;United States;
Apellis Pharmaceuticals, Inc.
2017 Phase 2 NCT03226678 United States;
Acalabrutinib
City of Hope Medical Center
2021 Phase 2 NCT04657094 United States;
BENDAMUSTINE HYDROCHLORIDE
Department of Medicine, Haugesund Hospital
2013 Phase 2 EUCTR2011-004835-30-FI Denmark;Finland;Norway;
2013 Phase 2 EUCTR2011-004835-30-DK Denmark;Finland;Norway;
2012 Phase 2 EUCTR2011-004835-30-NO Denmark;Finland;Norway;
BEXSERO – Sospensione iniettabile – Siringa preriempita
NOVARTIS PHARMA AG
2022 Phase 2 EUCTR2021-002039-40-IT Germany;Italy;Korea, Democratic People's Republic of;Spain;United Kingdom;United States;
BIV009
Bioverativ, a Sanofi company
2015 Phase 1 NCT02502903 Austria;
BIVV009
BIOVERATIV THERAPEUTICS INC
2018 Phase 3 EUCTR2017-003539-12-IT Australia;Austria;Belgium;Canada;Denmark;France;Germany;Hungary;Israel;Italy;Japan;Netherlands;New Zealand;Norway;Poland;Spain;Switzerland;United Kingdom;United States;
2018 Phase 3 EUCTR2017-003538-10-IT Australia;Austria;Belgium;Canada;France;Germany;Israel;Italy;Japan;Netherlands;New Zealand;Norway;Spain;United Kingdom;United States;
Bioverativ USA Inc.
2018 Phase 3 EUCTR2017-003539-12-NL Australia;Austria;Belgium;Canada;France;Germany;Israel;Italy;Japan;Netherlands;New Zealand;Norway;Spain;United Kingdom;United States;
2018 Phase 3 EUCTR2017-003539-12-ES Australia;Austria;Belgium;Canada;Denmark;France;Germany;Hungary;Israel;Italy;Japan;Norway;Poland;Spain;Switzerland;United Kingdom;United States;
2018 Phase 3 EUCTR2017-003539-12-DE Australia;Austria;Belgium;Canada;Denmark;France;Germany;Hungary;Israel;Italy;Japan;Netherlands;New Zealand;Norway;Poland;Spain;Switzerland;United Kingdom;United States;
2018 Phase 3 EUCTR2017-003538-10-ES Australia;Austria;Belgium;Canada;Denmark;France;Germany;Hungary;Israel;Italy;Japan;Netherlands;Norway;Poland;Spain;Switzerland;United Kingdom;United States;
2018 Phase 3 EUCTR2017-003538-10-DE Australia;Austria;Belgium;Canada;Denmark;France;Germany;Hungary;Israel;Italy;Japan;Netherlands;New Zealand;Norway;Poland;Spain;Switzerland;United Kingdom;United States;
2018 Phase 3 EUCTR2017-003538-10-BE Australia;Austria;Belgium;Canada;France;Germany;Israel;Italy;Japan;Netherlands;New Zealand;Norway;Spain;United Kingdom;United States;
2017 Phase 3 EUCTR2017-003539-12-AT Australia;Austria;Belgium;Canada;France;Germany;Israel;Italy;Japan;Netherlands;New Zealand;Norway;Spain;United Kingdom;United States;
2017 Phase 3 EUCTR2017-003538-10-AT Australia;Austria;Belgium;Canada;France;Germany;Israel;Italy;Japan;Netherlands;New Zealand;Norway;Spain;United Kingdom;United States;
Bioverativ USA, Inc.
2018 Phase 3 EUCTR2017-003539-12-GB Australia;Austria;Belgium;Canada;Denmark;France;Germany;Hungary;Israel;Italy;Japan;Netherlands;New Zealand;Norway;Poland;Spain;Switzerland;United Kingdom;United States;
2018 Phase 3 EUCTR2017-003539-12-BE Australia;Austria;Belgium;Canada;France;Germany;Israel;Italy;Japan;Netherlands;New Zealand;Norway;Spain;United Kingdom;United States;
2018 Phase 3 EUCTR2017-003538-10-NL Australia;Austria;Belgium;Canada;Denmark;France;Germany;Hungary;Israel;Italy;Japan;Netherlands;Norway;Poland;Spain;Switzerland;United Kingdom;United States;
Bioverativ a Sanofi Company Inc.
2018 Phase 3 EUCTR2017-003538-10-GB Australia;Austria;Belgium;Canada;Denmark;France;Germany;Hungary;Israel;Italy;Japan;Netherlands;New Zealand;Norway;Poland;Spain;Switzerland;United Kingdom;United States;
2017 Phase 3 EUCTR2017-003538-10-NO Australia;Austria;Belgium;Canada;France;Germany;Israel;Italy;Japan;Netherlands;New Zealand;Norway;Spain;United Kingdom;United States;
BIVV020
Bioverativ, a Sanofi company
2021 Phase 1 NCT04802057 Germany;Italy;Netherlands;Norway;United Kingdom;
2020 Phase 1 NCT04269551 Canada;Germany;Italy;Netherlands;Norway;Spain;United Kingdom;United States;
Bendamustine, Rituximab
Helse Fonna
2013 Phase 2 NCT02689986 Denmark;Finland;Norway;
Biological assessment
Centre Hospitalier Universitaire Dijon
2022 Phase 2 NCT05089227 France;
Blood sample
Centre Hospitalier Universitaire Dijon
2016 - NCT02828670 France;
University Hospital, Bordeaux
2019 - NCT04005638 France;
Blood samples
Centre Hospitalier Universitaire Dijon
2013 - NCT02158195 France;
Bortezomib
Gruppo Italiano Malattie EMatologiche dell'Adulto
2012 Phase 2 NCT01696474 Italy;
CD19/BCMA CAR T-cells
Zhejiang University
2021 Early Phase 1 NCT05263817 China;
CINRYZE® (C1 esterase inhibitor [human])
Academic Medical Center
2013 Phase 2 EUCTR2012-003710-13-NL Netherlands;
Ciclosporin
Tianjin Medical University General Hospital
2019 Phase 0 ChiCTR1900023476 China;
Combination of a single dose anti-CD20 antibody and bortezomib
Peking Union Medical College Hospital
2019 Phase 2 NCT04083014 China;
Cyclosporine
Assiut University
2021 Phase 3 NCT05057468 Egypt;
Eculizumab
University Hospital, Essen
2011 Phase 2 NCT01303952 Germany;
Fludarabine
University of Bergen
2005 Phase 2 NCT00373594 Norway;Russian Federation;
Fostamatinib 150 mg bid
Rigel Pharmaceuticals
2016 Phase 2 NCT02612558 Canada;United States;
Fostamatinib Disodium
RIGEL PHARMACEUTICALS, INC.
2019 Phase 3 EUCTR2018-004774-97-IT Australia;Austria;Belarus;Belgium;Bulgaria;Canada;Czech Republic;Czechia;Denmark;France;Georgia;Germany;Hungary;Italy;Netherlands;Norway;Romania;Russian Federation;Serbia;Spain;Ukraine;United Kingdom;United States;
Fostamatinib disodium
Rigel Pharmaceuticals
2019 Phase 3 NCT04138927 Australia;Austria;Belarus;Belgium;Bulgaria;Czechia;France;Georgia;Germany;Italy;Netherlands;Norway;Russian Federation;Serbia;Spain;Ukraine;United Kingdom;United States;
2019 Phase 3 NCT03764618 Australia;Austria;Belarus;Belgium;Bulgaria;Canada;Czechia;Denmark;France;Georgia;Germany;Hungary;Italy;Netherlands;Norway;Romania;Russian Federation;Serbia;Spain;Ukraine;United Kingdom;United States;
HIBERIX - POLVERE E SOLVENTE PER SOLUZIONE INIETTABILE PER USO INTRAMUSCOLARE 1 FLACONCINO DI POLVERE + 1 SIRINGA PRERIEMPITA DI SOLVENTE DA 0.5 ML
NOVARTIS PHARMA AG
2022 Phase 2 EUCTR2021-002039-40-IT Germany;Italy;Korea, Democratic People's Republic of;Spain;United Kingdom;United States;
INCB050465
INCYTE CORPORATION
2018 Phase 2 EUCTR2017-003652-22-IT Austria;France;Italy;United States;
Ueda Eiji
2021 Phase 3 JPRN-jRCT2051210140 Japan;U.S.A;
INCB050465 HYDROCHLORIDE
INCYTE CORPORATION
2021 Phase 3 EUCTR2021-002844-66-IT Austria;Belgium;Canada;France;Germany;Israel;Italy;Japan;Netherlands;Poland;Spain;Ukraine;United Kingdom;United States;
Incyte Coorporation
2018 Phase 2 EUCTR2017-003652-22-AT Austria;France;Italy;United States;
Incyte Corporation
2022 Phase 3 EUCTR2021-002844-66-NL Austria;Belgium;Canada;France;Germany;Israel;Italy;Japan;Netherlands;Poland;Spain;Ukraine;United Kingdom;United States;
2022 Phase 3 EUCTR2021-002844-66-ES Austria;Belgium;Canada;France;Germany;Israel;Italy;Japan;Netherlands;Poland;Spain;Ukraine;United Kingdom;United States;
Ibrutinib
Eugene Nikitin
2017 Phase 2 NCT03827603 Russian Federation;
Institute of Hematology & Blood Diseases Hospital
2020 Phase 2 NCT04398459 China;
Interleukine-2
University Hospital, Bordeaux
2017 Phase 1/Phase 2 NCT02389231 France;
Iptacopan
Novartis Farmacéutica, S.A.
2021 Phase 2 EUCTR2021-002039-40-ES Germany;Italy;Korea, Republic of;Spain;United Kingdom;United States;
Novartis Pharma AG
2021 Phase 2 EUCTR2021-002039-40-DE Germany;Italy;Korea, Republic of;Spain;United Kingdom;United States;
Novartis Pharmaceuticals
2021 Phase 2 NCT05086744 Germany;Spain;United Kingdom;
Isatuximab
SANOFI-AVENTIS RECHERCHE E DEVELOPPEMENT
2021 Phase 1;Phase 2 EUCTR2020-003880-24-IT Belgium;France;Germany;Hungary;Italy;Netherlands;United Kingdom;United States;
Sanofi-Aventis Recherche & Developpement
2021 Phase 1;Phase 2 EUCTR2020-003880-24-NL Belgium;France;Germany;Hungary;Italy;Netherlands;United Kingdom;United States;
2021 Phase 1;Phase 2 EUCTR2020-003880-24-HU Belgium;France;Germany;Hungary;Italy;Netherlands;United Kingdom;United States;
2021 Phase 1;Phase 2 EUCTR2020-003880-24-DE Belgium;France;Germany;Hungary;Italy;Netherlands;United Kingdom;United States;
Isatuximab SAR650984
Sanofi
2021 Phase 1/Phase 2 NCT04661033 Belgium;France;Germany;Hungary;Italy;Netherlands;United Kingdom;United States;
KZR-616
Kezar Life Sciences, Inc.
2020 Phase 2 NCT04039477 Australia;Italy;Poland;Russian Federation;United States;
Kappa (light chain)
Annexon, Inc
2020 Phase 2 EUCTR2020-003675-18-IT Austria;France;Germany;Hungary;Italy;Netherlands;Norway;Spain;United Kingdom;
LEVOCETIRIZINA DICLORIDRATO
SANOFI-AVENTIS RECHERCHE E DEVELOPPEMENT
2021 Phase 1;Phase 2 EUCTR2020-003880-24-IT Belgium;France;Germany;Hungary;Italy;Netherlands;United Kingdom;United States;
Levact
Department of Medicine, Haugesund Hospital
2013 Phase 2 EUCTR2011-004835-30-FI Denmark;Finland;Norway;
2013 Phase 2 EUCTR2011-004835-30-DK Denmark;Finland;Norway;
2012 Phase 2 EUCTR2011-004835-30-NO Denmark;Finland;Norway;
Levamisole
Institute of Hematology & Blood Diseases Hospital
2012 Phase 2 NCT01579110 China;
Levocitirizina
SANOFI-AVENTIS RECHERCHE E DEVELOPPEMENT
2021 Phase 1;Phase 2 EUCTR2020-003880-24-IT Belgium;France;Germany;Hungary;Italy;Netherlands;United Kingdom;United States;
M281
Janssen Research & Development, LLC
2019 Phase 2/Phase 3 NCT04119050 Czechia;France;Germany;Greece;Hungary;Israel;Italy;Netherlands;Poland;Spain;Ukraine;United Kingdom;United States;
Janssen-Cilag International NV
2020 Phase 2;Phase 3 EUCTR2019-000720-17-NL Czech Republic;Czechia;France;Germany;Greece;Hungary;Israel;Italy;Netherlands;Poland;Spain;Ukraine;United Kingdom;United States;
2020 Phase 2;Phase 3 EUCTR2019-000720-17-DE Czech Republic;Czechia;France;Germany;Greece;Hungary;Israel;Italy;Netherlands;Poland;Spain;Ukraine;United Kingdom;United States;
2019 Phase 2;Phase 3 EUCTR2019-000720-17-PL Czech Republic;Czechia;France;Germany;Greece;Hungary;Israel;Italy;Netherlands;Poland;Spain;Ukraine;United Kingdom;United States;
2019 Phase 2;Phase 3 EUCTR2019-000720-17-HU Czech Republic;Czechia;France;Germany;Greece;Hungary;Israel;Italy;Netherlands;Poland;Spain;Ukraine;United Kingdom;United States;
2019 Phase 2;Phase 3 EUCTR2019-000720-17-GR Czech Republic;Czechia;France;Germany;Greece;Hungary;Israel;Italy;Netherlands;Poland;Spain;Ukraine;United Kingdom;United States;
2019 Phase 2;Phase 3 EUCTR2019-000720-17-CZ Czech Republic;Czechia;France;Germany;Greece;Hungary;Israel;Italy;Netherlands;Poland;Spain;Ukraine;United Kingdom;United States;
MOMENTA PHARMACEUTICALS, Inc
2019 Phase 3 EUCTR2019-000720-17-IT Czech Republic;Czechia;France;Germany;Greece;Hungary;Israel;Italy;Netherlands;Poland;Spain;Ukraine;United Kingdom;United States;
Momenta Pharmaceuticals, Inc.
2019 Phase 2;Phase 3 EUCTR2019-000720-17-FR Czech Republic;Denmark;France;Germany;Greece;Hungary;Italy;Netherlands;Poland;Spain;United Kingdom;United States;
2019 Phase 2;Phase 3 EUCTR2019-000720-17-ES Czech Republic;Denmark;France;Germany;Greece;Hungary;Italy;Netherlands;Poland;Spain;United Kingdom;United States;
MENVEO – Polvere e soluzione per soluzione iniettabile
NOVARTIS PHARMA AG
2022 Phase 2 EUCTR2021-002039-40-IT Germany;Italy;Korea, Democratic People's Republic of;Spain;United Kingdom;United States;
MabThera
Department of Medicine, Haugesund Hospital
2013 Phase 2 EUCTR2011-004835-30-FI Denmark;Finland;Norway;
2013 Phase 2 EUCTR2011-004835-30-DK Denmark;Finland;Norway;
2012 Phase 2 EUCTR2011-004835-30-NO Denmark;Finland;Norway;
Mabthera or biosimilar Rituximab
Medical University of Vienna, Department of Internal medicine I
2016 Phase 2 EUCTR2016-002478-11-AT Austria;
Nimenrix
NOVARTIS PHARMA AG
2022 Phase 2 EUCTR2021-002039-40-IT Germany;Italy;Korea, Democratic People's Republic of;Spain;United Kingdom;United States;
Ninlaro
Assistance Publique - Hôpitaux de Paris
2019 Phase 2 NCT03965624 France;
Nipocalimab
Janssen Research & Development, LLC
2022 - NCT05221619 -
Janssen-Cilag International NV
2020 Phase 2;Phase 3 EUCTR2019-000720-17-NL Czech Republic;Czechia;France;Germany;Greece;Hungary;Israel;Italy;Netherlands;Poland;Spain;Ukraine;United Kingdom;United States;
2020 Phase 2;Phase 3 EUCTR2019-000720-17-DE Czech Republic;Czechia;France;Germany;Greece;Hungary;Israel;Italy;Netherlands;Poland;Spain;Ukraine;United Kingdom;United States;
2019 Phase 2;Phase 3 EUCTR2019-000720-17-PL Czech Republic;Czechia;France;Germany;Greece;Hungary;Israel;Italy;Netherlands;Poland;Spain;Ukraine;United Kingdom;United States;
2019 Phase 2;Phase 3 EUCTR2019-000720-17-HU Czech Republic;Czechia;France;Germany;Greece;Hungary;Israel;Italy;Netherlands;Poland;Spain;Ukraine;United Kingdom;United States;
2019 Phase 2;Phase 3 EUCTR2019-000720-17-GR Czech Republic;Czechia;France;Germany;Greece;Hungary;Israel;Italy;Netherlands;Poland;Spain;Ukraine;United Kingdom;United States;
2019 Phase 2;Phase 3 EUCTR2019-000720-17-CZ Czech Republic;Czechia;France;Germany;Greece;Hungary;Israel;Italy;Netherlands;Poland;Spain;Ukraine;United Kingdom;United States;
Orelabrutinib
Tianjin Medical University General Hospital
2021 Phase 4 ChiCTR2100045594 China;
PENTAMIDINA ISETIONATO
INCYTE CORPORATION
2021 Phase 3 EUCTR2021-002844-66-IT Austria;Belgium;Canada;France;Germany;Israel;Italy;Japan;Netherlands;Poland;Spain;Ukraine;United Kingdom;United States;
PRN1008
SANOFI-AVENTIS RECHERCHE E DEVELOPPEMENT
2021 Phase 2 EUCTR2021-001671-16-IT China;Denmark;Italy;Spain;United Kingdom;United States;
Sanofi aventis recherche et developpement
2021 Phase 2 EUCTR2021-001671-16-ES China;Denmark;Italy;Spain;United Kingdom;United States;
2021 Phase 2 EUCTR2021-001671-16-DK China;Denmark;Italy;Spain;United Kingdom;United States;
Parsaclisib
Incyte Corporation
2018 Phase 2 NCT03538041 Austria;France;Italy;United States;
Ueda Eiji
2021 Phase 3 JPRN-jRCT2051210140 Japan;U.S.A;
Parsaclisib (1 mg)
INCYTE CORPORATION
2021 Phase 3 EUCTR2021-002844-66-IT Austria;Belgium;Canada;France;Germany;Israel;Italy;Japan;Netherlands;Poland;Spain;Ukraine;United Kingdom;United States;
Incyte Corporation
2022 Phase 3 EUCTR2021-002844-66-NL Austria;Belgium;Canada;France;Germany;Israel;Italy;Japan;Netherlands;Poland;Spain;Ukraine;United Kingdom;United States;
2022 Phase 3 EUCTR2021-002844-66-ES Austria;Belgium;Canada;France;Germany;Israel;Italy;Japan;Netherlands;Poland;Spain;Ukraine;United Kingdom;United States;
Parsaclisib (2.5 mg)
INCYTE CORPORATION
2021 Phase 3 EUCTR2021-002844-66-IT Austria;Belgium;Canada;France;Germany;Israel;Italy;Japan;Netherlands;Poland;Spain;Ukraine;United Kingdom;United States;
Incyte Corporation
2022 Phase 3 EUCTR2021-002844-66-NL Austria;Belgium;Canada;France;Germany;Israel;Italy;Japan;Netherlands;Poland;Spain;Ukraine;United Kingdom;United States;
2022 Phase 3 EUCTR2021-002844-66-ES Austria;Belgium;Canada;France;Germany;Israel;Italy;Japan;Netherlands;Poland;Spain;Ukraine;United Kingdom;United States;
Parsaclisinib
Incyte Corporation
2022 Phase 3 NCT05073458 Austria;Belgium;Canada;France;Germany;Israel;Italy;Japan;Netherlands;Poland;Spain;United Kingdom;United States;
Pentamidine
INCYTE CORPORATION
2021 Phase 3 EUCTR2021-002844-66-IT Austria;Belgium;Canada;France;Germany;Israel;Italy;Japan;Netherlands;Poland;Spain;Ukraine;United Kingdom;United States;
Prednisolone + mabthera
Copenhagen University Hospital at Herlev
2005 Phase 3 NCT01134432 Denmark;
Prednisone
Institute of Hematology & Blood Diseases Hospital
2012 Phase 2 NCT01579110 China;
Prednisone, low dose rituximab
Fondazione Ospedale
2009 Phase 2 NCT01345708 Italy;
R788, fostamatinib disodium hexahydrate (in USPI/FPI)
RIGEL PHARMACEUTICALS, INC.
2020 Phase 3 EUCTR2019-001882-34-IT Australia;Austria;Belarus;Belgium;Bulgaria;Canada;Czech Republic;Czechia;Denmark;France;Georgia;Germany;Hungary;Italy;Netherlands;Norway;Romania;Russian Federation;Spain;Ukraine;United Kingdom;United States;
Rigel Pharmaceuticals, Inc.
2021 Phase 3 EUCTR2019-001882-34-NL Australia;Austria;Belarus;Belgium;Bulgaria;Canada;Czech Republic;Czechia;Denmark;France;Georgia;Germany;Hungary;Italy;Netherlands;Norway;Russian Federation;Serbia;Spain;Ukraine;United Kingdom;United States;
2020 Phase 3 EUCTR2019-001882-34-HU Australia;Austria;Belarus;Belgium;Bulgaria;Canada;Czech Republic;Denmark;France;Georgia;Germany;Hungary;Italy;Netherlands;Norway;Romania;Russian Federation;Serbia;Spain;Ukraine;United Kingdom;United States;
2020 Phase 3 EUCTR2019-001882-34-GB Australia;Austria;Belarus;Belgium;Bulgaria;Canada;Czech Republic;Denmark;France;Georgia;Germany;Hungary;Italy;Netherlands;Norway;Romania;Russian Federation;Serbia;Spain;Ukraine;United Kingdom;United States;
2020 Phase 3 EUCTR2019-001882-34-FR Australia;Austria;Belarus;Belgium;Bulgaria;Canada;Czech Republic;Denmark;France;Georgia;Germany;Hungary;Italy;Netherlands;Norway;Romania;Russian Federation;Serbia;Spain;Ukraine;United Kingdom;United States;
2020 Phase 3 EUCTR2019-001882-34-ES Australia;Austria;Belarus;Belgium;Bulgaria;Canada;Czech Republic;Denmark;France;Georgia;Germany;Hungary;Italy;Netherlands;Norway;Romania;Russian Federation;Serbia;Spain;Ukraine;United Kingdom;United States;
2020 Phase 3 EUCTR2019-001882-34-DK Australia;Austria;Belarus;Belgium;Bulgaria;Canada;Czech Republic;Czechia;Denmark;France;Georgia;Germany;Hungary;Italy;Netherlands;Norway;Romania;Russian Federation;Serbia;Spain;Ukraine;United Kingdom;United States;
2020 Phase 3 EUCTR2019-001882-34-DE Australia;Austria;Belarus;Belgium;Bulgaria;Canada;Czech Republic;Czechia;Denmark;France;Georgia;Germany;Hungary;Italy;Netherlands;Norway;Romania;Russian Federation;Serbia;Spain;Ukraine;United Kingdom;United States;
2020 Phase 3 EUCTR2019-001882-34-CZ Australia;Austria;Belarus;Belgium;Bulgaria;Canada;Czech Republic;Czechia;Denmark;France;Georgia;Germany;Hungary;Italy;Netherlands;Norway;Russian Federation;Serbia;Spain;Ukraine;United Kingdom;United States;
2020 Phase 3 EUCTR2019-001882-34-AT Australia;Austria;Belarus;Belgium;Bulgaria;Canada;Czech Republic;Czechia;Denmark;France;Georgia;Germany;Hungary;Italy;Netherlands;Norway;Russian Federation;Serbia;Spain;Ukraine;United Kingdom;United States;
2020 Phase 3 EUCTR2018-004774-97-NL Australia;Austria;Belarus;Belgium;Bulgaria;Canada;Czech Republic;Denmark;France;Georgia;Germany;Hungary;Italy;Netherlands;Norway;Romania;Russian Federation;Serbia;Spain;Ukraine;United Kingdom;United States;
2019 Phase 3 EUCTR2018-004774-97-HU Australia;Austria;Belarus;Belgium;Bulgaria;Canada;Czech Republic;Denmark;France;Georgia;Germany;Hungary;Italy;Netherlands;Norway;Romania;Russian Federation;Serbia;Spain;Ukraine;United Kingdom;United States;
2019 Phase 3 EUCTR2018-004774-97-GB Australia;Austria;Belarus;Belgium;Bulgaria;Canada;Czech Republic;Denmark;France;Georgia;Germany;Hungary;Italy;Netherlands;Norway;Romania;Russian Federation;Serbia;Spain;Ukraine;United Kingdom;United States;
2019 Phase 3 EUCTR2018-004774-97-ES Australia;Austria;Belarus;Belgium;Bulgaria;Canada;Czech Republic;Denmark;France;Georgia;Germany;Hungary;Italy;Netherlands;Norway;Romania;Russian Federation;Serbia;Spain;Ukraine;United Kingdom;United States;
2019 Phase 3 EUCTR2018-004774-97-DK Australia;Austria;Belarus;Belgium;Bulgaria;Canada;Czech Republic;Czechia;Denmark;France;Georgia;Germany;Hungary;Italy;Netherlands;Norway;Romania;Russian Federation;Serbia;Spain;Ukraine;United Kingdom;United States;
2019 Phase 3 EUCTR2018-004774-97-DE Australia;Austria;Belarus;Belgium;Bulgaria;Canada;Czech Republic;Czechia;Denmark;France;Georgia;Germany;Hungary;Italy;Netherlands;Norway;Romania;Russian Federation;Serbia;Spain;Ukraine;United Kingdom;United States;
2019 Phase 3 EUCTR2018-004774-97-CZ Australia;Austria;Belarus;Belgium;Bulgaria;Canada;Czech Republic;Czechia;Denmark;France;Georgia;Germany;Hungary;Italy;Netherlands;Norway;Romania;Russian Federation;Serbia;Spain;Ukraine;United Kingdom;United States;
2019 Phase 3 EUCTR2018-004774-97-BG Australia;Austria;Belarus;Belgium;Bulgaria;Canada;Czech Republic;Czechia;Denmark;France;Georgia;Germany;Hungary;Italy;Netherlands;Norway;Romania;Russian Federation;Serbia;Spain;Ukraine;United Kingdom;United States;
2019 Phase 3 EUCTR2018-004774-97-BE Australia;Austria;Belarus;Belgium;Bulgaria;Canada;Czech Republic;Czechia;Denmark;France;Georgia;Germany;Hungary;Italy;Netherlands;Norway;Romania;Russian Federation;Serbia;Spain;Ukraine;United Kingdom;United States;
2019 Phase 3 EUCTR2018-004774-97-AT Australia;Austria;Belarus;Belgium;Bulgaria;Canada;Czech Republic;Czechia;Denmark;France;Georgia;Germany;Hungary;Italy;Netherlands;Norway;Romania;Russian Federation;Serbia;Spain;Ukraine;United Kingdom;United States;
R935788
RIGEL PHARMACEUTICALS, INC.
2020 Phase 3 EUCTR2019-001882-34-IT Australia;Austria;Belarus;Belgium;Bulgaria;Canada;Czech Republic;Czechia;Denmark;France;Georgia;Germany;Hungary;Italy;Netherlands;Norway;Romania;Russian Federation;Spain;Ukraine;United Kingdom;United States;
2019 Phase 3 EUCTR2018-004774-97-IT Australia;Austria;Belarus;Belgium;Bulgaria;Canada;Czech Republic;Czechia;Denmark;France;Georgia;Germany;Hungary;Italy;Netherlands;Norway;Romania;Russian Federation;Serbia;Spain;Ukraine;United Kingdom;United States;
Rigel Pharmaceuticals, Inc.
2021 Phase 3 EUCTR2019-001882-34-NL Australia;Austria;Belarus;Belgium;Bulgaria;Canada;Czech Republic;Czechia;Denmark;France;Georgia;Germany;Hungary;Italy;Netherlands;Norway;Russian Federation;Serbia;Spain;Ukraine;United Kingdom;United States;
2020 Phase 3 EUCTR2019-001882-34-HU Australia;Austria;Belarus;Belgium;Bulgaria;Canada;Czech Republic;Denmark;France;Georgia;Germany;Hungary;Italy;Netherlands;Norway;Romania;Russian Federation;Serbia;Spain;Ukraine;United Kingdom;United States;
2020 Phase 3 EUCTR2019-001882-34-GB Australia;Austria;Belarus;Belgium;Bulgaria;Canada;Czech Republic;Denmark;France;Georgia;Germany;Hungary;Italy;Netherlands;Norway;Romania;Russian Federation;Serbia;Spain;Ukraine;United Kingdom;United States;
2020 Phase 3 EUCTR2019-001882-34-FR Australia;Austria;Belarus;Belgium;Bulgaria;Canada;Czech Republic;Denmark;France;Georgia;Germany;Hungary;Italy;Netherlands;Norway;Romania;Russian Federation;Serbia;Spain;Ukraine;United Kingdom;United States;
2020 Phase 3 EUCTR2019-001882-34-ES Australia;Austria;Belarus;Belgium;Bulgaria;Canada;Czech Republic;Denmark;France;Georgia;Germany;Hungary;Italy;Netherlands;Norway;Romania;Russian Federation;Serbia;Spain;Ukraine;United Kingdom;United States;
2020 Phase 3 EUCTR2019-001882-34-DK Australia;Austria;Belarus;Belgium;Bulgaria;Canada;Czech Republic;Czechia;Denmark;France;Georgia;Germany;Hungary;Italy;Netherlands;Norway;Romania;Russian Federation;Serbia;Spain;Ukraine;United Kingdom;United States;
2020 Phase 3 EUCTR2019-001882-34-DE Australia;Austria;Belarus;Belgium;Bulgaria;Canada;Czech Republic;Czechia;Denmark;France;Georgia;Germany;Hungary;Italy;Netherlands;Norway;Romania;Russian Federation;Serbia;Spain;Ukraine;United Kingdom;United States;
2020 Phase 3 EUCTR2019-001882-34-CZ Australia;Austria;Belarus;Belgium;Bulgaria;Canada;Czech Republic;Czechia;Denmark;France;Georgia;Germany;Hungary;Italy;Netherlands;Norway;Russian Federation;Serbia;Spain;Ukraine;United Kingdom;United States;
2020 Phase 3 EUCTR2019-001882-34-AT Australia;Austria;Belarus;Belgium;Bulgaria;Canada;Czech Republic;Czechia;Denmark;France;Georgia;Germany;Hungary;Italy;Netherlands;Norway;Russian Federation;Serbia;Spain;Ukraine;United Kingdom;United States;
2020 Phase 3 EUCTR2018-004774-97-NL Australia;Austria;Belarus;Belgium;Bulgaria;Canada;Czech Republic;Denmark;France;Georgia;Germany;Hungary;Italy;Netherlands;Norway;Romania;Russian Federation;Serbia;Spain;Ukraine;United Kingdom;United States;
2019 Phase 3 EUCTR2018-004774-97-HU Australia;Austria;Belarus;Belgium;Bulgaria;Canada;Czech Republic;Denmark;France;Georgia;Germany;Hungary;Italy;Netherlands;Norway;Romania;Russian Federation;Serbia;Spain;Ukraine;United Kingdom;United States;
2019 Phase 3 EUCTR2018-004774-97-GB Australia;Austria;Belarus;Belgium;Bulgaria;Canada;Czech Republic;Denmark;France;Georgia;Germany;Hungary;Italy;Netherlands;Norway;Romania;Russian Federation;Serbia;Spain;Ukraine;United Kingdom;United States;
2019 Phase 3 EUCTR2018-004774-97-ES Australia;Austria;Belarus;Belgium;Bulgaria;Canada;Czech Republic;Denmark;France;Georgia;Germany;Hungary;Italy;Netherlands;Norway;Romania;Russian Federation;Serbia;Spain;Ukraine;United Kingdom;United States;
2019 Phase 3 EUCTR2018-004774-97-DK Australia;Austria;Belarus;Belgium;Bulgaria;Canada;Czech Republic;Czechia;Denmark;France;Georgia;Germany;Hungary;Italy;Netherlands;Norway;Romania;Russian Federation;Serbia;Spain;Ukraine;United Kingdom;United States;
2019 Phase 3 EUCTR2018-004774-97-DE Australia;Austria;Belarus;Belgium;Bulgaria;Canada;Czech Republic;Czechia;Denmark;France;Georgia;Germany;Hungary;Italy;Netherlands;Norway;Romania;Russian Federation;Serbia;Spain;Ukraine;United Kingdom;United States;
2019 Phase 3 EUCTR2018-004774-97-CZ Australia;Austria;Belarus;Belgium;Bulgaria;Canada;Czech Republic;Czechia;Denmark;France;Georgia;Germany;Hungary;Italy;Netherlands;Norway;Romania;Russian Federation;Serbia;Spain;Ukraine;United Kingdom;United States;
2019 Phase 3 EUCTR2018-004774-97-BG Australia;Austria;Belarus;Belgium;Bulgaria;Canada;Czech Republic;Czechia;Denmark;France;Georgia;Germany;Hungary;Italy;Netherlands;Norway;Romania;Russian Federation;Serbia;Spain;Ukraine;United Kingdom;United States;
2019 Phase 3 EUCTR2018-004774-97-BE Australia;Austria;Belarus;Belgium;Bulgaria;Canada;Czech Republic;Czechia;Denmark;France;Georgia;Germany;Hungary;Italy;Netherlands;Norway;Romania;Russian Federation;Serbia;Spain;Ukraine;United Kingdom;United States;
2019 Phase 3 EUCTR2018-004774-97-AT Australia;Austria;Belarus;Belgium;Bulgaria;Canada;Czech Republic;Czechia;Denmark;France;Georgia;Germany;Hungary;Italy;Netherlands;Norway;Romania;Russian Federation;Serbia;Spain;Ukraine;United Kingdom;United States;
RVT-1401
Immunovant Sciences GmbH
2020 Phase 2 EUCTR2019-003924-19-PL Bulgaria;Hungary;Israel;Korea, Republic of;Poland;Spain;Thailand;United Kingdom;United States;
2020 Phase 2 EUCTR2019-003924-19-HU Bulgaria;Hungary;Israel;Korea, Republic of;Poland;Spain;Thailand;United Kingdom;United States;
2020 Phase 2 EUCTR2019-003924-19-GB Israel;Korea, Republic of;Romania;Spain;Thailand;United Kingdom;United States;
2020 Phase 2 EUCTR2019-003924-19-ES Bulgaria;Hungary;Israel;Korea, Republic of;Poland;Romania;Spain;Thailand;United Kingdom;United States;
2020 Phase 2 EUCTR2019-003924-19-BG Bulgaria;Hungary;Israel;Korea, Republic of;Poland;Spain;Thailand;United Kingdom;United States;
RVT-1401 340 mg/weekly
Immunovant Sciences GmbH
2020 Phase 2 NCT04253236 Israel;Korea, Republic of;Spain;Thailand;United Kingdom;United States;
RVT-1401 680 mg/weekly
Immunovant Sciences GmbH
2020 Phase 2 NCT04253236 Israel;Korea, Republic of;Spain;Thailand;United Kingdom;United States;
Rapamycin
Tianjin Medical University General Hospital
2019 Phase 0 ChiCTR1900023476 China;
Raptiva 100 mg/ml powder and solvent for solution for injection
Merck Serono International S.A.
2009 - EUCTR2007-001377-28-PT Austria;France;Germany;Netherlands;Portugal;
2008 - EUCTR2007-001377-28-NL Austria;France;Germany;Netherlands;Portugal;
2008 - EUCTR2007-001377-28-FR Austria;France;Germany;Netherlands;Portugal;
2008 - EUCTR2007-001377-28-DE Austria;France;Germany;Netherlands;Portugal;
2008 - EUCTR2007-001377-28-AT Austria;France;Germany;Netherlands;Portugal;
Recombinant humanized IgG4 monoclonal antibody
Annexon, Inc.
2021 Phase 2 EUCTR2020-005854-90-AT Austria;
Recombinant humanized monoclonal antibody: IgG4 (heavy chain)
Annexon, Inc
2020 Phase 2 EUCTR2020-003675-18-IT Austria;France;Germany;Hungary;Italy;Netherlands;Norway;Spain;United Kingdom;
Rilzabrutinib
SANOFI-AVENTIS RECHERCHE E DEVELOPPEMENT
2021 Phase 2 EUCTR2021-001671-16-IT China;Denmark;Italy;Spain;United Kingdom;United States;
Sanofi
2021 Phase 2 NCT05002777 China;Denmark;Italy;Spain;United Kingdom;United States;
Sanofi aventis recherche et developpement
2021 Phase 2 EUCTR2021-001671-16-ES China;Denmark;Italy;Spain;United Kingdom;United States;
2021 Phase 2 EUCTR2021-001671-16-DK China;Denmark;Italy;Spain;United Kingdom;United States;
Rituximab
Assiut University
2021 Phase 3 NCT05057481 Egypt;
2021 Phase 3 NCT05057468 Egypt;
OSPEDALE MAGGIORE DI MILANO (IRCCS)
2008 - EUCTR2008-006713-25-IT Italy;
University of Bergen
2005 Phase 2 NCT00373594 Norway;Russian Federation;
Rituximab (MABTHERA® or RITUXAN®).
University Hospital, Toulouse
2009 - NCT00960713 France;
Rituximab (Mabthera®)
Assistance Publique - Hôpitaux de Paris
2011 Phase 3 NCT01181154 France;
SAR444671
SANOFI-AVENTIS RECHERCHE E DEVELOPPEMENT
2021 Phase 2 EUCTR2021-001671-16-IT China;Denmark;Italy;Spain;United Kingdom;United States;
Sanofi aventis recherche et developpement
2021 Phase 2 EUCTR2021-001671-16-ES China;Denmark;Italy;Spain;United Kingdom;United States;
2021 Phase 2 EUCTR2021-001671-16-DK China;Denmark;Italy;Spain;United Kingdom;United States;
SAR650984
SANOFI-AVENTIS RECHERCHE E DEVELOPPEMENT
2021 Phase 1;Phase 2 EUCTR2020-003880-24-IT Belgium;France;Germany;Hungary;Italy;Netherlands;United Kingdom;United States;
Sanofi-Aventis Recherche & Developpement
2021 Phase 1;Phase 2 EUCTR2020-003880-24-NL Belgium;France;Germany;Hungary;Italy;Netherlands;United Kingdom;United States;
2021 Phase 1;Phase 2 EUCTR2020-003880-24-HU Belgium;France;Germany;Hungary;Italy;Netherlands;United Kingdom;United States;
2021 Phase 1;Phase 2 EUCTR2020-003880-24-DE Belgium;France;Germany;Hungary;Italy;Netherlands;United Kingdom;United States;
SYNT001
Alexion Pharmaceuticals, Inc.
2021 Phase 2 EUCTR2021-001211-90-ES France;Germany;Italy;Korea, Republic of;Spain;United Kingdom;United States;
2020 Phase 2 EUCTR2019-004055-37-ES Australia;Belgium;Canada;France;Germany;Italy;Korea, Republic of;Netherlands;Russian Federation;Spain;Taiwan;United Kingdom;United States;
Sirolimus
Children's Hospital of Philadelphia
2006 Phase 1/Phase 2 NCT00392951 United States;
Soliris (R)
Universitätsklinikum Essen
2010 - EUCTR2009-016966-97-DE Germany;
Spleen sample
Centre Hospitalier Universitaire Dijon
2016 - NCT02828670 France;
Sutimlimab
Bioverativ, a Sanofi company
2018 Phase 3 NCT03347396 Australia;Austria;Belgium;Canada;France;Germany;Israel;Italy;Japan;Netherlands;Norway;Spain;United Kingdom;United States;
Sanofi
2021 Phase 3 NCT05132127 Japan;
Tanaka Tomoyuki
2021 Phase 3 JPRN-jRCT2031210392 Japan;
Sutimlimab (BIVV009)
Bioverativ, a Sanofi company
2018 Phase 3 NCT03347422 Australia;Austria;Belgium;Canada;France;Germany;Israel;Italy;Japan;Netherlands;Norway;Spain;United Kingdom;United States;
TNT009
BIOVERATIV THERAPEUTICS INC
2018 Phase 3 EUCTR2017-003539-12-IT Australia;Austria;Belgium;Canada;Denmark;France;Germany;Hungary;Israel;Italy;Japan;Netherlands;New Zealand;Norway;Poland;Spain;Switzerland;United Kingdom;United States;
2018 Phase 3 EUCTR2017-003538-10-IT Australia;Austria;Belgium;Canada;France;Germany;Israel;Italy;Japan;Netherlands;New Zealand;Norway;Spain;United Kingdom;United States;
Bioverativ USA Inc.
2018 Phase 3 EUCTR2017-003539-12-NL Australia;Austria;Belgium;Canada;France;Germany;Israel;Italy;Japan;Netherlands;New Zealand;Norway;Spain;United Kingdom;United States;
2018 Phase 3 EUCTR2017-003539-12-DE Australia;Austria;Belgium;Canada;Denmark;France;Germany;Hungary;Israel;Italy;Japan;Netherlands;New Zealand;Norway;Poland;Spain;Switzerland;United Kingdom;United States;
2018 Phase 3 EUCTR2017-003538-10-DE Australia;Austria;Belgium;Canada;Denmark;France;Germany;Hungary;Israel;Italy;Japan;Netherlands;New Zealand;Norway;Poland;Spain;Switzerland;United Kingdom;United States;
2018 Phase 3 EUCTR2017-003538-10-BE Australia;Austria;Belgium;Canada;France;Germany;Israel;Italy;Japan;Netherlands;New Zealand;Norway;Spain;United Kingdom;United States;
2017 Phase 3 EUCTR2017-003539-12-AT Australia;Austria;Belgium;Canada;France;Germany;Israel;Italy;Japan;Netherlands;New Zealand;Norway;Spain;United Kingdom;United States;
2017 Phase 3 EUCTR2017-003538-10-AT Australia;Austria;Belgium;Canada;France;Germany;Israel;Italy;Japan;Netherlands;New Zealand;Norway;Spain;United Kingdom;United States;
Bioverativ USA, Inc.
2018 Phase 3 EUCTR2017-003539-12-GB Australia;Austria;Belgium;Canada;Denmark;France;Germany;Hungary;Israel;Italy;Japan;Netherlands;New Zealand;Norway;Poland;Spain;Switzerland;United Kingdom;United States;
2018 Phase 3 EUCTR2017-003539-12-BE Australia;Austria;Belgium;Canada;France;Germany;Israel;Italy;Japan;Netherlands;New Zealand;Norway;Spain;United Kingdom;United States;
Bioverativ a Sanofi Company Inc.
2018 Phase 3 EUCTR2017-003538-10-GB Australia;Austria;Belgium;Canada;Denmark;France;Germany;Hungary;Israel;Italy;Japan;Netherlands;New Zealand;Norway;Poland;Spain;Switzerland;United Kingdom;United States;
2017 Phase 3 EUCTR2017-003538-10-NO Australia;Austria;Belgium;Canada;France;Germany;Israel;Italy;Japan;Netherlands;New Zealand;Norway;Spain;United Kingdom;United States;
TRIMETOPRIM + SULFAMETOSSAZOLO *
INCYTE CORPORATION
2021 Phase 3 EUCTR2021-002844-66-IT Austria;Belgium;Canada;France;Germany;Israel;Italy;Japan;Netherlands;Poland;Spain;Ukraine;United Kingdom;United States;
Tacrolimus
Peking Union Medical College Hospital
2019 Phase 4 NCT03918265 China;
Treatment intervention
Centre Hospitalier Universitaire Dijon
2022 Phase 2 NCT05089227 France;
Treatment standard
Centre Hospitalier Universitaire Dijon
2022 Phase 2 NCT05089227 France;
Trimethoprim-sulfamethoxazole
INCYTE CORPORATION
2021 Phase 3 EUCTR2021-002844-66-IT Austria;Belgium;Canada;France;Germany;Israel;Italy;Japan;Netherlands;Poland;Spain;Ukraine;United Kingdom;United States;
Urine sample
University Hospital, Bordeaux
2019 - NCT04005638 France;
VACCINO CONTRO IL MEMINGOCOCCO DI GRUPPO B
NOVARTIS PHARMA AG
2022 Phase 2 EUCTR2021-002039-40-IT Germany;Italy;Korea, Democratic People's Republic of;Spain;United Kingdom;United States;
VACCINO HAEMOPHILUS INFLUENZAE B CONIUGATO CON TOSSOIDETETANICO
NOVARTIS PHARMA AG
2022 Phase 2 EUCTR2021-002039-40-IT Germany;Italy;Korea, Democratic People's Republic of;Spain;United Kingdom;United States;
VACCINO POLISACCARIDICO ANTI-MENINGOCOCCICO (A.C.Y E W-135)
NOVARTIS PHARMA AG
2022 Phase 2 EUCTR2021-002039-40-IT Germany;Italy;Korea, Democratic People's Republic of;Spain;United Kingdom;United States;
VELCADE*EV 1FL 3,5MG 1MG/ML
G.I.M.E.M.A. GRUPPO ITALIANO MALATTIE EMATOLOGICHE DELL'ADULTO
2012 Phase 2 EUCTR2011-006329-42-IT Italy;
LNP023 HYDROCHLORIDE SALT
Novartis Farmacéutica, S.A.
2021 Phase 2 EUCTR2021-002039-40-ES Germany;Italy;Korea, Republic of;Spain;United Kingdom;United States;
Novartis Pharma AG
2021 Phase 2 EUCTR2021-002039-40-DE Germany;Italy;Korea, Republic of;Spain;United Kingdom;United States;
NOVARTIS PHARMA AG
2022 Phase 2 EUCTR2021-002039-40-IT Germany;Italy;Korea, Democratic People's Republic of;Spain;United Kingdom;United States;
ALXN1830
ALEXION PHARMACEUTICALS INCORPORATED
2021 Phase 2 EUCTR2021-001211-90-IT France;Germany;Italy;Korea, Republic of;Spain;United Kingdom;United States;
Alexion Pharmaceuticals
2022 Phase 2 NCT04956276 United States;
2021 Phase 2 NCT04256148 United States;
2018 Phase 1/Phase 2 NCT03075878 Jordan;United States;
Alexion Pharmaceuticals, Inc.
2021 Phase 2 EUCTR2021-001211-90-ES France;Germany;Italy;Korea, Republic of;Spain;United Kingdom;United States;
2020 Phase 2 EUCTR2019-004055-37-ES Australia;Belgium;Canada;France;Germany;Italy;Korea, Republic of;Netherlands;Russian Federation;Spain;Taiwan;United Kingdom;United States;
ANX005
Annexon, Inc
2020 Phase 2 EUCTR2020-003675-18-IT Austria;France;Germany;Hungary;Italy;Netherlands;Norway;Spain;United Kingdom;
Annexon, Inc.
2021 Phase 2 EUCTR2020-005854-90-AT Austria;
2021 Phase 2 EUCTR2020-003675-18-DE Australia;Austria;Bulgaria;Czechia;France;Germany;Italy;Spain;United Kingdom;United States;
2021 Phase 2 EUCTR2020-003675-18-BG Australia;Austria;Bulgaria;Czechia;France;Germany;Italy;Spain;United States;
2021 Phase 2 EUCTR2020-003675-18-AT Australia;Austria;Bulgaria;Czechia;France;Germany;Italy;Spain;United Kingdom;United States;
APL-2
APELLIS PHARMACEUTCIALS, INC.
2018 Phase 2 EUCTR2017-003363-35-IT Italy;United States;
Apellis Pharmaceuticals, Inc.
2017 Phase 2 NCT03226678 United States;
Acalabrutinib
City of Hope Medical Center
2021 Phase 2 NCT04657094 United States;
BENDAMUSTINE HYDROCHLORIDE
Department of Medicine, Haugesund Hospital
2013 Phase 2 EUCTR2011-004835-30-FI Denmark;Finland;Norway;
2013 Phase 2 EUCTR2011-004835-30-DK Denmark;Finland;Norway;
2012 Phase 2 EUCTR2011-004835-30-NO Denmark;Finland;Norway;
BEXSERO – Sospensione iniettabile – Siringa preriempita
NOVARTIS PHARMA AG
2022 Phase 2 EUCTR2021-002039-40-IT Germany;Italy;Korea, Democratic People's Republic of;Spain;United Kingdom;United States;
BIV009
Bioverativ, a Sanofi company
2015 Phase 1 NCT02502903 Austria;
BIVV009
BIOVERATIV THERAPEUTICS INC
2018 Phase 3 EUCTR2017-003539-12-IT Australia;Austria;Belgium;Canada;Denmark;France;Germany;Hungary;Israel;Italy;Japan;Netherlands;New Zealand;Norway;Poland;Spain;Switzerland;United Kingdom;United States;
2018 Phase 3 EUCTR2017-003538-10-IT Australia;Austria;Belgium;Canada;France;Germany;Israel;Italy;Japan;Netherlands;New Zealand;Norway;Spain;United Kingdom;United States;
Bioverativ USA Inc.
2018 Phase 3 EUCTR2017-003539-12-NL Australia;Austria;Belgium;Canada;France;Germany;Israel;Italy;Japan;Netherlands;New Zealand;Norway;Spain;United Kingdom;United States;
2018 Phase 3 EUCTR2017-003539-12-ES Australia;Austria;Belgium;Canada;Denmark;France;Germany;Hungary;Israel;Italy;Japan;Norway;Poland;Spain;Switzerland;United Kingdom;United States;
2018 Phase 3 EUCTR2017-003539-12-DE Australia;Austria;Belgium;Canada;Denmark;France;Germany;Hungary;Israel;Italy;Japan;Netherlands;New Zealand;Norway;Poland;Spain;Switzerland;United Kingdom;United States;
2018 Phase 3 EUCTR2017-003538-10-ES Australia;Austria;Belgium;Canada;Denmark;France;Germany;Hungary;Israel;Italy;Japan;Netherlands;Norway;Poland;Spain;Switzerland;United Kingdom;United States;
2018 Phase 3 EUCTR2017-003538-10-DE Australia;Austria;Belgium;Canada;Denmark;France;Germany;Hungary;Israel;Italy;Japan;Netherlands;New Zealand;Norway;Poland;Spain;Switzerland;United Kingdom;United States;
2018 Phase 3 EUCTR2017-003538-10-BE Australia;Austria;Belgium;Canada;France;Germany;Israel;Italy;Japan;Netherlands;New Zealand;Norway;Spain;United Kingdom;United States;
2017 Phase 3 EUCTR2017-003539-12-AT Australia;Austria;Belgium;Canada;France;Germany;Israel;Italy;Japan;Netherlands;New Zealand;Norway;Spain;United Kingdom;United States;
2017 Phase 3 EUCTR2017-003538-10-AT Australia;Austria;Belgium;Canada;France;Germany;Israel;Italy;Japan;Netherlands;New Zealand;Norway;Spain;United Kingdom;United States;
Bioverativ USA, Inc.
2018 Phase 3 EUCTR2017-003539-12-GB Australia;Austria;Belgium;Canada;Denmark;France;Germany;Hungary;Israel;Italy;Japan;Netherlands;New Zealand;Norway;Poland;Spain;Switzerland;United Kingdom;United States;
2018 Phase 3 EUCTR2017-003539-12-BE Australia;Austria;Belgium;Canada;France;Germany;Israel;Italy;Japan;Netherlands;New Zealand;Norway;Spain;United Kingdom;United States;
2018 Phase 3 EUCTR2017-003538-10-NL Australia;Austria;Belgium;Canada;Denmark;France;Germany;Hungary;Israel;Italy;Japan;Netherlands;Norway;Poland;Spain;Switzerland;United Kingdom;United States;
Bioverativ a Sanofi Company Inc.
2018 Phase 3 EUCTR2017-003538-10-GB Australia;Austria;Belgium;Canada;Denmark;France;Germany;Hungary;Israel;Italy;Japan;Netherlands;New Zealand;Norway;Poland;Spain;Switzerland;United Kingdom;United States;
2017 Phase 3 EUCTR2017-003538-10-NO Australia;Austria;Belgium;Canada;France;Germany;Israel;Italy;Japan;Netherlands;New Zealand;Norway;Spain;United Kingdom;United States;
BIVV020
Bioverativ, a Sanofi company
2021 Phase 1 NCT04802057 Germany;Italy;Netherlands;Norway;United Kingdom;
2020 Phase 1 NCT04269551 Canada;Germany;Italy;Netherlands;Norway;Spain;United Kingdom;United States;
Bendamustine, Rituximab
Helse Fonna
2013 Phase 2 NCT02689986 Denmark;Finland;Norway;
Biological assessment
Centre Hospitalier Universitaire Dijon
2022 Phase 2 NCT05089227 France;
Blood sample
Centre Hospitalier Universitaire Dijon
2016 - NCT02828670 France;
University Hospital, Bordeaux
2019 - NCT04005638 France;
Blood samples
Centre Hospitalier Universitaire Dijon
2013 - NCT02158195 France;
Bortezomib
Gruppo Italiano Malattie EMatologiche dell'Adulto
2012 Phase 2 NCT01696474 Italy;
CD19/BCMA CAR T-cells
Zhejiang University
2021 Early Phase 1 NCT05263817 China;
CINRYZE® (C1 esterase inhibitor [human])
Academic Medical Center
2013 Phase 2 EUCTR2012-003710-13-NL Netherlands;
Ciclosporin
Tianjin Medical University General Hospital
2019 Phase 0 ChiCTR1900023476 China;
Combination of a single dose anti-CD20 antibody and bortezomib
Peking Union Medical College Hospital
2019 Phase 2 NCT04083014 China;
Cyclosporine
Assiut University
2021 Phase 3 NCT05057468 Egypt;
Eculizumab
University Hospital, Essen
2011 Phase 2 NCT01303952 Germany;
Fludarabine
University of Bergen
2005 Phase 2 NCT00373594 Norway;Russian Federation;
Fostamatinib 150 mg bid
Rigel Pharmaceuticals
2016 Phase 2 NCT02612558 Canada;United States;
Fostamatinib Disodium
RIGEL PHARMACEUTICALS, INC.
2019 Phase 3 EUCTR2018-004774-97-IT Australia;Austria;Belarus;Belgium;Bulgaria;Canada;Czech Republic;Czechia;Denmark;France;Georgia;Germany;Hungary;Italy;Netherlands;Norway;Romania;Russian Federation;Serbia;Spain;Ukraine;United Kingdom;United States;
Fostamatinib disodium
Rigel Pharmaceuticals
2019 Phase 3 NCT04138927 Australia;Austria;Belarus;Belgium;Bulgaria;Czechia;France;Georgia;Germany;Italy;Netherlands;Norway;Russian Federation;Serbia;Spain;Ukraine;United Kingdom;United States;
2019 Phase 3 NCT03764618 Australia;Austria;Belarus;Belgium;Bulgaria;Canada;Czechia;Denmark;France;Georgia;Germany;Hungary;Italy;Netherlands;Norway;Romania;Russian Federation;Serbia;Spain;Ukraine;United Kingdom;United States;
HIBERIX - POLVERE E SOLVENTE PER SOLUZIONE INIETTABILE PER USO INTRAMUSCOLARE 1 FLACONCINO DI POLVERE + 1 SIRINGA PRERIEMPITA DI SOLVENTE DA 0.5 ML
NOVARTIS PHARMA AG
2022 Phase 2 EUCTR2021-002039-40-IT Germany;Italy;Korea, Democratic People's Republic of;Spain;United Kingdom;United States;
INCB050465
INCYTE CORPORATION
2018 Phase 2 EUCTR2017-003652-22-IT Austria;France;Italy;United States;
Ueda Eiji
2021 Phase 3 JPRN-jRCT2051210140 Japan;U.S.A;
INCB050465 HYDROCHLORIDE
INCYTE CORPORATION
2021 Phase 3 EUCTR2021-002844-66-IT Austria;Belgium;Canada;France;Germany;Israel;Italy;Japan;Netherlands;Poland;Spain;Ukraine;United Kingdom;United States;
Incyte Coorporation
2018 Phase 2 EUCTR2017-003652-22-AT Austria;France;Italy;United States;
Incyte Corporation
2022 Phase 3 EUCTR2021-002844-66-NL Austria;Belgium;Canada;France;Germany;Israel;Italy;Japan;Netherlands;Poland;Spain;Ukraine;United Kingdom;United States;
2022 Phase 3 EUCTR2021-002844-66-ES Austria;Belgium;Canada;France;Germany;Israel;Italy;Japan;Netherlands;Poland;Spain;Ukraine;United Kingdom;United States;
Ibrutinib
Eugene Nikitin
2017 Phase 2 NCT03827603 Russian Federation;
Institute of Hematology & Blood Diseases Hospital
2020 Phase 2 NCT04398459 China;
Interleukine-2
University Hospital, Bordeaux
2017 Phase 1/Phase 2 NCT02389231 France;
Iptacopan
Novartis Farmacéutica, S.A.
2021 Phase 2 EUCTR2021-002039-40-ES Germany;Italy;Korea, Republic of;Spain;United Kingdom;United States;
Novartis Pharma AG
2021 Phase 2 EUCTR2021-002039-40-DE Germany;Italy;Korea, Republic of;Spain;United Kingdom;United States;
Novartis Pharmaceuticals
2021 Phase 2 NCT05086744 Germany;Spain;United Kingdom;
Isatuximab
SANOFI-AVENTIS RECHERCHE E DEVELOPPEMENT
2021 Phase 1;Phase 2 EUCTR2020-003880-24-IT Belgium;France;Germany;Hungary;Italy;Netherlands;United Kingdom;United States;
Sanofi-Aventis Recherche & Developpement
2021 Phase 1;Phase 2 EUCTR2020-003880-24-NL Belgium;France;Germany;Hungary;Italy;Netherlands;United Kingdom;United States;
2021 Phase 1;Phase 2 EUCTR2020-003880-24-HU Belgium;France;Germany;Hungary;Italy;Netherlands;United Kingdom;United States;
2021 Phase 1;Phase 2 EUCTR2020-003880-24-DE Belgium;France;Germany;Hungary;Italy;Netherlands;United Kingdom;United States;
Isatuximab SAR650984
Sanofi
2021 Phase 1/Phase 2 NCT04661033 Belgium;France;Germany;Hungary;Italy;Netherlands;United Kingdom;United States;
KZR-616
Kezar Life Sciences, Inc.
2020 Phase 2 NCT04039477 Australia;Italy;Poland;Russian Federation;United States;
Kappa (light chain)
Annexon, Inc
2020 Phase 2 EUCTR2020-003675-18-IT Austria;France;Germany;Hungary;Italy;Netherlands;Norway;Spain;United Kingdom;
LEVOCETIRIZINA DICLORIDRATO
SANOFI-AVENTIS RECHERCHE E DEVELOPPEMENT
2021 Phase 1;Phase 2 EUCTR2020-003880-24-IT Belgium;France;Germany;Hungary;Italy;Netherlands;United Kingdom;United States;
Levact
Department of Medicine, Haugesund Hospital
2013 Phase 2 EUCTR2011-004835-30-FI Denmark;Finland;Norway;
2013 Phase 2 EUCTR2011-004835-30-DK Denmark;Finland;Norway;
2012 Phase 2 EUCTR2011-004835-30-NO Denmark;Finland;Norway;
Levamisole
Institute of Hematology & Blood Diseases Hospital
2012 Phase 2 NCT01579110 China;
Levocitirizina
SANOFI-AVENTIS RECHERCHE E DEVELOPPEMENT
2021 Phase 1;Phase 2 EUCTR2020-003880-24-IT Belgium;France;Germany;Hungary;Italy;Netherlands;United Kingdom;United States;
M281
Janssen Research & Development, LLC
2019 Phase 2/Phase 3 NCT04119050 Czechia;France;Germany;Greece;Hungary;Israel;Italy;Netherlands;Poland;Spain;Ukraine;United Kingdom;United States;
Janssen-Cilag International NV
2020 Phase 2;Phase 3 EUCTR2019-000720-17-NL Czech Republic;Czechia;France;Germany;Greece;Hungary;Israel;Italy;Netherlands;Poland;Spain;Ukraine;United Kingdom;United States;
2020 Phase 2;Phase 3 EUCTR2019-000720-17-DE Czech Republic;Czechia;France;Germany;Greece;Hungary;Israel;Italy;Netherlands;Poland;Spain;Ukraine;United Kingdom;United States;
2019 Phase 2;Phase 3 EUCTR2019-000720-17-PL Czech Republic;Czechia;France;Germany;Greece;Hungary;Israel;Italy;Netherlands;Poland;Spain;Ukraine;United Kingdom;United States;
2019 Phase 2;Phase 3 EUCTR2019-000720-17-HU Czech Republic;Czechia;France;Germany;Greece;Hungary;Israel;Italy;Netherlands;Poland;Spain;Ukraine;United Kingdom;United States;
2019 Phase 2;Phase 3 EUCTR2019-000720-17-GR Czech Republic;Czechia;France;Germany;Greece;Hungary;Israel;Italy;Netherlands;Poland;Spain;Ukraine;United Kingdom;United States;
2019 Phase 2;Phase 3 EUCTR2019-000720-17-CZ Czech Republic;Czechia;France;Germany;Greece;Hungary;Israel;Italy;Netherlands;Poland;Spain;Ukraine;United Kingdom;United States;
MOMENTA PHARMACEUTICALS, Inc
2019 Phase 3 EUCTR2019-000720-17-IT Czech Republic;Czechia;France;Germany;Greece;Hungary;Israel;Italy;Netherlands;Poland;Spain;Ukraine;United Kingdom;United States;
Momenta Pharmaceuticals, Inc.
2019 Phase 2;Phase 3 EUCTR2019-000720-17-FR Czech Republic;Denmark;France;Germany;Greece;Hungary;Italy;Netherlands;Poland;Spain;United Kingdom;United States;
2019 Phase 2;Phase 3 EUCTR2019-000720-17-ES Czech Republic;Denmark;France;Germany;Greece;Hungary;Italy;Netherlands;Poland;Spain;United Kingdom;United States;
MENVEO – Polvere e soluzione per soluzione iniettabile
NOVARTIS PHARMA AG
2022 Phase 2 EUCTR2021-002039-40-IT Germany;Italy;Korea, Democratic People's Republic of;Spain;United Kingdom;United States;
MabThera
Department of Medicine, Haugesund Hospital
2013 Phase 2 EUCTR2011-004835-30-FI Denmark;Finland;Norway;
2013 Phase 2 EUCTR2011-004835-30-DK Denmark;Finland;Norway;
2012 Phase 2 EUCTR2011-004835-30-NO Denmark;Finland;Norway;
Mabthera or biosimilar Rituximab
Medical University of Vienna, Department of Internal medicine I
2016 Phase 2 EUCTR2016-002478-11-AT Austria;
Nimenrix
NOVARTIS PHARMA AG
2022 Phase 2 EUCTR2021-002039-40-IT Germany;Italy;Korea, Democratic People's Republic of;Spain;United Kingdom;United States;
Ninlaro
Assistance Publique - Hôpitaux de Paris
2019 Phase 2 NCT03965624 France;
Nipocalimab
Janssen Research & Development, LLC
2022 - NCT05221619 -
Janssen-Cilag International NV
2020 Phase 2;Phase 3 EUCTR2019-000720-17-NL Czech Republic;Czechia;France;Germany;Greece;Hungary;Israel;Italy;Netherlands;Poland;Spain;Ukraine;United Kingdom;United States;
2020 Phase 2;Phase 3 EUCTR2019-000720-17-DE Czech Republic;Czechia;France;Germany;Greece;Hungary;Israel;Italy;Netherlands;Poland;Spain;Ukraine;United Kingdom;United States;
2019 Phase 2;Phase 3 EUCTR2019-000720-17-PL Czech Republic;Czechia;France;Germany;Greece;Hungary;Israel;Italy;Netherlands;Poland;Spain;Ukraine;United Kingdom;United States;
2019 Phase 2;Phase 3 EUCTR2019-000720-17-HU Czech Republic;Czechia;France;Germany;Greece;Hungary;Israel;Italy;Netherlands;Poland;Spain;Ukraine;United Kingdom;United States;
2019 Phase 2;Phase 3 EUCTR2019-000720-17-GR Czech Republic;Czechia;France;Germany;Greece;Hungary;Israel;Italy;Netherlands;Poland;Spain;Ukraine;United Kingdom;United States;
2019 Phase 2;Phase 3 EUCTR2019-000720-17-CZ Czech Republic;Czechia;France;Germany;Greece;Hungary;Israel;Italy;Netherlands;Poland;Spain;Ukraine;United Kingdom;United States;
Orelabrutinib
Tianjin Medical University General Hospital
2021 Phase 4 ChiCTR2100045594 China;
PENTAMIDINA ISETIONATO
INCYTE CORPORATION
2021 Phase 3 EUCTR2021-002844-66-IT Austria;Belgium;Canada;France;Germany;Israel;Italy;Japan;Netherlands;Poland;Spain;Ukraine;United Kingdom;United States;
PRN1008
SANOFI-AVENTIS RECHERCHE E DEVELOPPEMENT
2021 Phase 2 EUCTR2021-001671-16-IT China;Denmark;Italy;Spain;United Kingdom;United States;
Sanofi aventis recherche et developpement
2021 Phase 2 EUCTR2021-001671-16-ES China;Denmark;Italy;Spain;United Kingdom;United States;
2021 Phase 2 EUCTR2021-001671-16-DK China;Denmark;Italy;Spain;United Kingdom;United States;
Parsaclisib
Incyte Corporation
2018 Phase 2 NCT03538041 Austria;France;Italy;United States;
Ueda Eiji
2021 Phase 3 JPRN-jRCT2051210140 Japan;U.S.A;
Parsaclisib (1 mg)
INCYTE CORPORATION
2021 Phase 3 EUCTR2021-002844-66-IT Austria;Belgium;Canada;France;Germany;Israel;Italy;Japan;Netherlands;Poland;Spain;Ukraine;United Kingdom;United States;
Incyte Corporation
2022 Phase 3 EUCTR2021-002844-66-NL Austria;Belgium;Canada;France;Germany;Israel;Italy;Japan;Netherlands;Poland;Spain;Ukraine;United Kingdom;United States;
2022 Phase 3 EUCTR2021-002844-66-ES Austria;Belgium;Canada;France;Germany;Israel;Italy;Japan;Netherlands;Poland;Spain;Ukraine;United Kingdom;United States;
Parsaclisib (2.5 mg)
INCYTE CORPORATION
2021 Phase 3 EUCTR2021-002844-66-IT Austria;Belgium;Canada;France;Germany;Israel;Italy;Japan;Netherlands;Poland;Spain;Ukraine;United Kingdom;United States;
Incyte Corporation
2022 Phase 3 EUCTR2021-002844-66-NL Austria;Belgium;Canada;France;Germany;Israel;Italy;Japan;Netherlands;Poland;Spain;Ukraine;United Kingdom;United States;
2022 Phase 3 EUCTR2021-002844-66-ES Austria;Belgium;Canada;France;Germany;Israel;Italy;Japan;Netherlands;Poland;Spain;Ukraine;United Kingdom;United States;
Parsaclisinib
Incyte Corporation
2022 Phase 3 NCT05073458 Austria;Belgium;Canada;France;Germany;Israel;Italy;Japan;Netherlands;Poland;Spain;United Kingdom;United States;
Pentamidine
INCYTE CORPORATION
2021 Phase 3 EUCTR2021-002844-66-IT Austria;Belgium;Canada;France;Germany;Israel;Italy;Japan;Netherlands;Poland;Spain;Ukraine;United Kingdom;United States;
Prednisolone + mabthera
Copenhagen University Hospital at Herlev
2005 Phase 3 NCT01134432 Denmark;
Prednisone
Institute of Hematology & Blood Diseases Hospital
2012 Phase 2 NCT01579110 China;
Prednisone, low dose rituximab
Fondazione Ospedale
2009 Phase 2 NCT01345708 Italy;
R788, fostamatinib disodium hexahydrate (in USPI/FPI)
RIGEL PHARMACEUTICALS, INC.
2020 Phase 3 EUCTR2019-001882-34-IT Australia;Austria;Belarus;Belgium;Bulgaria;Canada;Czech Republic;Czechia;Denmark;France;Georgia;Germany;Hungary;Italy;Netherlands;Norway;Romania;Russian Federation;Spain;Ukraine;United Kingdom;United States;
Rigel Pharmaceuticals, Inc.
2021 Phase 3 EUCTR2019-001882-34-NL Australia;Austria;Belarus;Belgium;Bulgaria;Canada;Czech Republic;Czechia;Denmark;France;Georgia;Germany;Hungary;Italy;Netherlands;Norway;Russian Federation;Serbia;Spain;Ukraine;United Kingdom;United States;
2020 Phase 3 EUCTR2019-001882-34-HU Australia;Austria;Belarus;Belgium;Bulgaria;Canada;Czech Republic;Denmark;France;Georgia;Germany;Hungary;Italy;Netherlands;Norway;Romania;Russian Federation;Serbia;Spain;Ukraine;United Kingdom;United States;
2020 Phase 3 EUCTR2019-001882-34-GB Australia;Austria;Belarus;Belgium;Bulgaria;Canada;Czech Republic;Denmark;France;Georgia;Germany;Hungary;Italy;Netherlands;Norway;Romania;Russian Federation;Serbia;Spain;Ukraine;United Kingdom;United States;
2020 Phase 3 EUCTR2019-001882-34-FR Australia;Austria;Belarus;Belgium;Bulgaria;Canada;Czech Republic;Denmark;France;Georgia;Germany;Hungary;Italy;Netherlands;Norway;Romania;Russian Federation;Serbia;Spain;Ukraine;United Kingdom;United States;
2020 Phase 3 EUCTR2019-001882-34-ES Australia;Austria;Belarus;Belgium;Bulgaria;Canada;Czech Republic;Denmark;France;Georgia;Germany;Hungary;Italy;Netherlands;Norway;Romania;Russian Federation;Serbia;Spain;Ukraine;United Kingdom;United States;
2020 Phase 3 EUCTR2019-001882-34-DK Australia;Austria;Belarus;Belgium;Bulgaria;Canada;Czech Republic;Czechia;Denmark;France;Georgia;Germany;Hungary;Italy;Netherlands;Norway;Romania;Russian Federation;Serbia;Spain;Ukraine;United Kingdom;United States;
2020 Phase 3 EUCTR2019-001882-34-DE Australia;Austria;Belarus;Belgium;Bulgaria;Canada;Czech Republic;Czechia;Denmark;France;Georgia;Germany;Hungary;Italy;Netherlands;Norway;Romania;Russian Federation;Serbia;Spain;Ukraine;United Kingdom;United States;
2020 Phase 3 EUCTR2019-001882-34-CZ Australia;Austria;Belarus;Belgium;Bulgaria;Canada;Czech Republic;Czechia;Denmark;France;Georgia;Germany;Hungary;Italy;Netherlands;Norway;Russian Federation;Serbia;Spain;Ukraine;United Kingdom;United States;
2020 Phase 3 EUCTR2019-001882-34-AT Australia;Austria;Belarus;Belgium;Bulgaria;Canada;Czech Republic;Czechia;Denmark;France;Georgia;Germany;Hungary;Italy;Netherlands;Norway;Russian Federation;Serbia;Spain;Ukraine;United Kingdom;United States;
2020 Phase 3 EUCTR2018-004774-97-NL Australia;Austria;Belarus;Belgium;Bulgaria;Canada;Czech Republic;Denmark;France;Georgia;Germany;Hungary;Italy;Netherlands;Norway;Romania;Russian Federation;Serbia;Spain;Ukraine;United Kingdom;United States;
2019 Phase 3 EUCTR2018-004774-97-HU Australia;Austria;Belarus;Belgium;Bulgaria;Canada;Czech Republic;Denmark;France;Georgia;Germany;Hungary;Italy;Netherlands;Norway;Romania;Russian Federation;Serbia;Spain;Ukraine;United Kingdom;United States;
2019 Phase 3 EUCTR2018-004774-97-GB Australia;Austria;Belarus;Belgium;Bulgaria;Canada;Czech Republic;Denmark;France;Georgia;Germany;Hungary;Italy;Netherlands;Norway;Romania;Russian Federation;Serbia;Spain;Ukraine;United Kingdom;United States;
2019 Phase 3 EUCTR2018-004774-97-ES Australia;Austria;Belarus;Belgium;Bulgaria;Canada;Czech Republic;Denmark;France;Georgia;Germany;Hungary;Italy;Netherlands;Norway;Romania;Russian Federation;Serbia;Spain;Ukraine;United Kingdom;United States;
2019 Phase 3 EUCTR2018-004774-97-DK Australia;Austria;Belarus;Belgium;Bulgaria;Canada;Czech Republic;Czechia;Denmark;France;Georgia;Germany;Hungary;Italy;Netherlands;Norway;Romania;Russian Federation;Serbia;Spain;Ukraine;United Kingdom;United States;
2019 Phase 3 EUCTR2018-004774-97-DE Australia;Austria;Belarus;Belgium;Bulgaria;Canada;Czech Republic;Czechia;Denmark;France;Georgia;Germany;Hungary;Italy;Netherlands;Norway;Romania;Russian Federation;Serbia;Spain;Ukraine;United Kingdom;United States;
2019 Phase 3 EUCTR2018-004774-97-CZ Australia;Austria;Belarus;Belgium;Bulgaria;Canada;Czech Republic;Czechia;Denmark;France;Georgia;Germany;Hungary;Italy;Netherlands;Norway;Romania;Russian Federation;Serbia;Spain;Ukraine;United Kingdom;United States;
2019 Phase 3 EUCTR2018-004774-97-BG Australia;Austria;Belarus;Belgium;Bulgaria;Canada;Czech Republic;Czechia;Denmark;France;Georgia;Germany;Hungary;Italy;Netherlands;Norway;Romania;Russian Federation;Serbia;Spain;Ukraine;United Kingdom;United States;
2019 Phase 3 EUCTR2018-004774-97-BE Australia;Austria;Belarus;Belgium;Bulgaria;Canada;Czech Republic;Czechia;Denmark;France;Georgia;Germany;Hungary;Italy;Netherlands;Norway;Romania;Russian Federation;Serbia;Spain;Ukraine;United Kingdom;United States;
2019 Phase 3 EUCTR2018-004774-97-AT Australia;Austria;Belarus;Belgium;Bulgaria;Canada;Czech Republic;Czechia;Denmark;France;Georgia;Germany;Hungary;Italy;Netherlands;Norway;Romania;Russian Federation;Serbia;Spain;Ukraine;United Kingdom;United States;
R935788
RIGEL PHARMACEUTICALS, INC.
2020 Phase 3 EUCTR2019-001882-34-IT Australia;Austria;Belarus;Belgium;Bulgaria;Canada;Czech Republic;Czechia;Denmark;France;Georgia;Germany;Hungary;Italy;Netherlands;Norway;Romania;Russian Federation;Spain;Ukraine;United Kingdom;United States;
2019 Phase 3 EUCTR2018-004774-97-IT Australia;Austria;Belarus;Belgium;Bulgaria;Canada;Czech Republic;Czechia;Denmark;France;Georgia;Germany;Hungary;Italy;Netherlands;Norway;Romania;Russian Federation;Serbia;Spain;Ukraine;United Kingdom;United States;
Rigel Pharmaceuticals, Inc.
2021 Phase 3 EUCTR2019-001882-34-NL Australia;Austria;Belarus;Belgium;Bulgaria;Canada;Czech Republic;Czechia;Denmark;France;Georgia;Germany;Hungary;Italy;Netherlands;Norway;Russian Federation;Serbia;Spain;Ukraine;United Kingdom;United States;
2020 Phase 3 EUCTR2019-001882-34-HU Australia;Austria;Belarus;Belgium;Bulgaria;Canada;Czech Republic;Denmark;France;Georgia;Germany;Hungary;Italy;Netherlands;Norway;Romania;Russian Federation;Serbia;Spain;Ukraine;United Kingdom;United States;
2020 Phase 3 EUCTR2019-001882-34-GB Australia;Austria;Belarus;Belgium;Bulgaria;Canada;Czech Republic;Denmark;France;Georgia;Germany;Hungary;Italy;Netherlands;Norway;Romania;Russian Federation;Serbia;Spain;Ukraine;United Kingdom;United States;
2020 Phase 3 EUCTR2019-001882-34-FR Australia;Austria;Belarus;Belgium;Bulgaria;Canada;Czech Republic;Denmark;France;Georgia;Germany;Hungary;Italy;Netherlands;Norway;Romania;Russian Federation;Serbia;Spain;Ukraine;United Kingdom;United States;
2020 Phase 3 EUCTR2019-001882-34-ES Australia;Austria;Belarus;Belgium;Bulgaria;Canada;Czech Republic;Denmark;France;Georgia;Germany;Hungary;Italy;Netherlands;Norway;Romania;Russian Federation;Serbia;Spain;Ukraine;United Kingdom;United States;
2020 Phase 3 EUCTR2019-001882-34-DK Australia;Austria;Belarus;Belgium;Bulgaria;Canada;Czech Republic;Czechia;Denmark;France;Georgia;Germany;Hungary;Italy;Netherlands;Norway;Romania;Russian Federation;Serbia;Spain;Ukraine;United Kingdom;United States;
2020 Phase 3 EUCTR2019-001882-34-DE Australia;Austria;Belarus;Belgium;Bulgaria;Canada;Czech Republic;Czechia;Denmark;France;Georgia;Germany;Hungary;Italy;Netherlands;Norway;Romania;Russian Federation;Serbia;Spain;Ukraine;United Kingdom;United States;
2020 Phase 3 EUCTR2019-001882-34-CZ Australia;Austria;Belarus;Belgium;Bulgaria;Canada;Czech Republic;Czechia;Denmark;France;Georgia;Germany;Hungary;Italy;Netherlands;Norway;Russian Federation;Serbia;Spain;Ukraine;United Kingdom;United States;
2020 Phase 3 EUCTR2019-001882-34-AT Australia;Austria;Belarus;Belgium;Bulgaria;Canada;Czech Republic;Czechia;Denmark;France;Georgia;Germany;Hungary;Italy;Netherlands;Norway;Russian Federation;Serbia;Spain;Ukraine;United Kingdom;United States;
2020 Phase 3 EUCTR2018-004774-97-NL Australia;Austria;Belarus;Belgium;Bulgaria;Canada;Czech Republic;Denmark;France;Georgia;Germany;Hungary;Italy;Netherlands;Norway;Romania;Russian Federation;Serbia;Spain;Ukraine;United Kingdom;United States;
2019 Phase 3 EUCTR2018-004774-97-HU Australia;Austria;Belarus;Belgium;Bulgaria;Canada;Czech Republic;Denmark;France;Georgia;Germany;Hungary;Italy;Netherlands;Norway;Romania;Russian Federation;Serbia;Spain;Ukraine;United Kingdom;United States;
2019 Phase 3 EUCTR2018-004774-97-GB Australia;Austria;Belarus;Belgium;Bulgaria;Canada;Czech Republic;Denmark;France;Georgia;Germany;Hungary;Italy;Netherlands;Norway;Romania;Russian Federation;Serbia;Spain;Ukraine;United Kingdom;United States;
2019 Phase 3 EUCTR2018-004774-97-ES Australia;Austria;Belarus;Belgium;Bulgaria;Canada;Czech Republic;Denmark;France;Georgia;Germany;Hungary;Italy;Netherlands;Norway;Romania;Russian Federation;Serbia;Spain;Ukraine;United Kingdom;United States;
2019 Phase 3 EUCTR2018-004774-97-DK Australia;Austria;Belarus;Belgium;Bulgaria;Canada;Czech Republic;Czechia;Denmark;France;Georgia;Germany;Hungary;Italy;Netherlands;Norway;Romania;Russian Federation;Serbia;Spain;Ukraine;United Kingdom;United States;
2019 Phase 3 EUCTR2018-004774-97-DE Australia;Austria;Belarus;Belgium;Bulgaria;Canada;Czech Republic;Czechia;Denmark;France;Georgia;Germany;Hungary;Italy;Netherlands;Norway;Romania;Russian Federation;Serbia;Spain;Ukraine;United Kingdom;United States;
2019 Phase 3 EUCTR2018-004774-97-CZ Australia;Austria;Belarus;Belgium;Bulgaria;Canada;Czech Republic;Czechia;Denmark;France;Georgia;Germany;Hungary;Italy;Netherlands;Norway;Romania;Russian Federation;Serbia;Spain;Ukraine;United Kingdom;United States;
2019 Phase 3 EUCTR2018-004774-97-BG Australia;Austria;Belarus;Belgium;Bulgaria;Canada;Czech Republic;Czechia;Denmark;France;Georgia;Germany;Hungary;Italy;Netherlands;Norway;Romania;Russian Federation;Serbia;Spain;Ukraine;United Kingdom;United States;
2019 Phase 3 EUCTR2018-004774-97-BE Australia;Austria;Belarus;Belgium;Bulgaria;Canada;Czech Republic;Czechia;Denmark;France;Georgia;Germany;Hungary;Italy;Netherlands;Norway;Romania;Russian Federation;Serbia;Spain;Ukraine;United Kingdom;United States;
2019 Phase 3 EUCTR2018-004774-97-AT Australia;Austria;Belarus;Belgium;Bulgaria;Canada;Czech Republic;Czechia;Denmark;France;Georgia;Germany;Hungary;Italy;Netherlands;Norway;Romania;Russian Federation;Serbia;Spain;Ukraine;United Kingdom;United States;
RVT-1401
Immunovant Sciences GmbH
2020 Phase 2 EUCTR2019-003924-19-PL Bulgaria;Hungary;Israel;Korea, Republic of;Poland;Spain;Thailand;United Kingdom;United States;
2020 Phase 2 EUCTR2019-003924-19-HU Bulgaria;Hungary;Israel;Korea, Republic of;Poland;Spain;Thailand;United Kingdom;United States;
2020 Phase 2 EUCTR2019-003924-19-GB Israel;Korea, Republic of;Romania;Spain;Thailand;United Kingdom;United States;
2020 Phase 2 EUCTR2019-003924-19-ES Bulgaria;Hungary;Israel;Korea, Republic of;Poland;Romania;Spain;Thailand;United Kingdom;United States;
2020 Phase 2 EUCTR2019-003924-19-BG Bulgaria;Hungary;Israel;Korea, Republic of;Poland;Spain;Thailand;United Kingdom;United States;
RVT-1401 340 mg/weekly
Immunovant Sciences GmbH
2020 Phase 2 NCT04253236 Israel;Korea, Republic of;Spain;Thailand;United Kingdom;United States;
RVT-1401 680 mg/weekly
Immunovant Sciences GmbH
2020 Phase 2 NCT04253236 Israel;Korea, Republic of;Spain;Thailand;United Kingdom;United States;
Rapamycin
Tianjin Medical University General Hospital
2019 Phase 0 ChiCTR1900023476 China;
Raptiva 100 mg/ml powder and solvent for solution for injection
Merck Serono International S.A.
2009 - EUCTR2007-001377-28-PT Austria;France;Germany;Netherlands;Portugal;
2008 - EUCTR2007-001377-28-NL Austria;France;Germany;Netherlands;Portugal;
2008 - EUCTR2007-001377-28-FR Austria;France;Germany;Netherlands;Portugal;
2008 - EUCTR2007-001377-28-DE Austria;France;Germany;Netherlands;Portugal;
2008 - EUCTR2007-001377-28-AT Austria;France;Germany;Netherlands;Portugal;
Recombinant humanized IgG4 monoclonal antibody
Annexon, Inc.
2021 Phase 2 EUCTR2020-005854-90-AT Austria;
Recombinant humanized monoclonal antibody: IgG4 (heavy chain)
Annexon, Inc
2020 Phase 2 EUCTR2020-003675-18-IT Austria;France;Germany;Hungary;Italy;Netherlands;Norway;Spain;United Kingdom;
Rilzabrutinib
SANOFI-AVENTIS RECHERCHE E DEVELOPPEMENT
2021 Phase 2 EUCTR2021-001671-16-IT China;Denmark;Italy;Spain;United Kingdom;United States;
Sanofi
2021 Phase 2 NCT05002777 China;Denmark;Italy;Spain;United Kingdom;United States;
Sanofi aventis recherche et developpement
2021 Phase 2 EUCTR2021-001671-16-ES China;Denmark;Italy;Spain;United Kingdom;United States;
2021 Phase 2 EUCTR2021-001671-16-DK China;Denmark;Italy;Spain;United Kingdom;United States;
Rituximab
Assiut University
2021 Phase 3 NCT05057481 Egypt;
2021 Phase 3 NCT05057468 Egypt;
OSPEDALE MAGGIORE DI MILANO (IRCCS)
2008 - EUCTR2008-006713-25-IT Italy;
University of Bergen
2005 Phase 2 NCT00373594 Norway;Russian Federation;
Rituximab (MABTHERA® or RITUXAN®).
University Hospital, Toulouse
2009 - NCT00960713 France;
Rituximab (Mabthera®)
Assistance Publique - Hôpitaux de Paris
2011 Phase 3 NCT01181154 France;
SAR444671
SANOFI-AVENTIS RECHERCHE E DEVELOPPEMENT
2021 Phase 2 EUCTR2021-001671-16-IT China;Denmark;Italy;Spain;United Kingdom;United States;
Sanofi aventis recherche et developpement
2021 Phase 2 EUCTR2021-001671-16-ES China;Denmark;Italy;Spain;United Kingdom;United States;
2021 Phase 2 EUCTR2021-001671-16-DK China;Denmark;Italy;Spain;United Kingdom;United States;
SAR650984
SANOFI-AVENTIS RECHERCHE E DEVELOPPEMENT
2021 Phase 1;Phase 2 EUCTR2020-003880-24-IT Belgium;France;Germany;Hungary;Italy;Netherlands;United Kingdom;United States;
Sanofi-Aventis Recherche & Developpement
2021 Phase 1;Phase 2 EUCTR2020-003880-24-NL Belgium;France;Germany;Hungary;Italy;Netherlands;United Kingdom;United States;
2021 Phase 1;Phase 2 EUCTR2020-003880-24-HU Belgium;France;Germany;Hungary;Italy;Netherlands;United Kingdom;United States;
2021 Phase 1;Phase 2 EUCTR2020-003880-24-DE Belgium;France;Germany;Hungary;Italy;Netherlands;United Kingdom;United States;
SYNT001
Alexion Pharmaceuticals, Inc.
2021 Phase 2 EUCTR2021-001211-90-ES France;Germany;Italy;Korea, Republic of;Spain;United Kingdom;United States;
2020 Phase 2 EUCTR2019-004055-37-ES Australia;Belgium;Canada;France;Germany;Italy;Korea, Republic of;Netherlands;Russian Federation;Spain;Taiwan;United Kingdom;United States;
Sirolimus
Children's Hospital of Philadelphia
2006 Phase 1/Phase 2 NCT00392951 United States;
Soliris (R)
Universitätsklinikum Essen
2010 - EUCTR2009-016966-97-DE Germany;
Spleen sample
Centre Hospitalier Universitaire Dijon
2016 - NCT02828670 France;
Sutimlimab
Bioverativ, a Sanofi company
2018 Phase 3 NCT03347396 Australia;Austria;Belgium;Canada;France;Germany;Israel;Italy;Japan;Netherlands;Norway;Spain;United Kingdom;United States;
Sanofi
2021 Phase 3 NCT05132127 Japan;
Tanaka Tomoyuki
2021 Phase 3 JPRN-jRCT2031210392 Japan;
Sutimlimab (BIVV009)
Bioverativ, a Sanofi company
2018 Phase 3 NCT03347422 Australia;Austria;Belgium;Canada;France;Germany;Israel;Italy;Japan;Netherlands;Norway;Spain;United Kingdom;United States;
TNT009
BIOVERATIV THERAPEUTICS INC
2018 Phase 3 EUCTR2017-003539-12-IT Australia;Austria;Belgium;Canada;Denmark;France;Germany;Hungary;Israel;Italy;Japan;Netherlands;New Zealand;Norway;Poland;Spain;Switzerland;United Kingdom;United States;
2018 Phase 3 EUCTR2017-003538-10-IT Australia;Austria;Belgium;Canada;France;Germany;Israel;Italy;Japan;Netherlands;New Zealand;Norway;Spain;United Kingdom;United States;
Bioverativ USA Inc.
2018 Phase 3 EUCTR2017-003539-12-NL Australia;Austria;Belgium;Canada;France;Germany;Israel;Italy;Japan;Netherlands;New Zealand;Norway;Spain;United Kingdom;United States;
2018 Phase 3 EUCTR2017-003539-12-DE Australia;Austria;Belgium;Canada;Denmark;France;Germany;Hungary;Israel;Italy;Japan;Netherlands;New Zealand;Norway;Poland;Spain;Switzerland;United Kingdom;United States;
2018 Phase 3 EUCTR2017-003538-10-DE Australia;Austria;Belgium;Canada;Denmark;France;Germany;Hungary;Israel;Italy;Japan;Netherlands;New Zealand;Norway;Poland;Spain;Switzerland;United Kingdom;United States;
2018 Phase 3 EUCTR2017-003538-10-BE Australia;Austria;Belgium;Canada;France;Germany;Israel;Italy;Japan;Netherlands;New Zealand;Norway;Spain;United Kingdom;United States;
2017 Phase 3 EUCTR2017-003539-12-AT Australia;Austria;Belgium;Canada;France;Germany;Israel;Italy;Japan;Netherlands;New Zealand;Norway;Spain;United Kingdom;United States;
2017 Phase 3 EUCTR2017-003538-10-AT Australia;Austria;Belgium;Canada;France;Germany;Israel;Italy;Japan;Netherlands;New Zealand;Norway;Spain;United Kingdom;United States;
Bioverativ USA, Inc.
2018 Phase 3 EUCTR2017-003539-12-GB Australia;Austria;Belgium;Canada;Denmark;France;Germany;Hungary;Israel;Italy;Japan;Netherlands;New Zealand;Norway;Poland;Spain;Switzerland;United Kingdom;United States;
2018 Phase 3 EUCTR2017-003539-12-BE Australia;Austria;Belgium;Canada;France;Germany;Israel;Italy;Japan;Netherlands;New Zealand;Norway;Spain;United Kingdom;United States;
Bioverativ a Sanofi Company Inc.
2018 Phase 3 EUCTR2017-003538-10-GB Australia;Austria;Belgium;Canada;Denmark;France;Germany;Hungary;Israel;Italy;Japan;Netherlands;New Zealand;Norway;Poland;Spain;Switzerland;United Kingdom;United States;
2017 Phase 3 EUCTR2017-003538-10-NO Australia;Austria;Belgium;Canada;France;Germany;Israel;Italy;Japan;Netherlands;New Zealand;Norway;Spain;United Kingdom;United States;
TRIMETOPRIM + SULFAMETOSSAZOLO *
INCYTE CORPORATION
2021 Phase 3 EUCTR2021-002844-66-IT Austria;Belgium;Canada;France;Germany;Israel;Italy;Japan;Netherlands;Poland;Spain;Ukraine;United Kingdom;United States;
Tacrolimus
Peking Union Medical College Hospital
2019 Phase 4 NCT03918265 China;
Treatment intervention
Centre Hospitalier Universitaire Dijon
2022 Phase 2 NCT05089227 France;
Treatment standard
Centre Hospitalier Universitaire Dijon
2022 Phase 2 NCT05089227 France;
Trimethoprim-sulfamethoxazole
INCYTE CORPORATION
2021 Phase 3 EUCTR2021-002844-66-IT Austria;Belgium;Canada;France;Germany;Israel;Italy;Japan;Netherlands;Poland;Spain;Ukraine;United Kingdom;United States;
Urine sample
University Hospital, Bordeaux
2019 - NCT04005638 France;
VACCINO CONTRO IL MEMINGOCOCCO DI GRUPPO B
NOVARTIS PHARMA AG
2022 Phase 2 EUCTR2021-002039-40-IT Germany;Italy;Korea, Democratic People's Republic of;Spain;United Kingdom;United States;
VACCINO HAEMOPHILUS INFLUENZAE B CONIUGATO CON TOSSOIDETETANICO
NOVARTIS PHARMA AG
2022 Phase 2 EUCTR2021-002039-40-IT Germany;Italy;Korea, Democratic People's Republic of;Spain;United Kingdom;United States;
VACCINO POLISACCARIDICO ANTI-MENINGOCOCCICO (A.C.Y E W-135)
NOVARTIS PHARMA AG
2022 Phase 2 EUCTR2021-002039-40-IT Germany;Italy;Korea, Democratic People's Republic of;Spain;United Kingdom;United States;
VELCADE*EV 1FL 3,5MG 1MG/ML
G.I.M.E.M.A. GRUPPO ITALIANO MALATTIE EMATOLOGICHE DELL'ADULTO
2012 Phase 2 EUCTR2011-006329-42-IT Italy;
LNP023 HYDROCHLORIDE SALT
Novartis Farmacéutica, S.A.
2021 Phase 2 EUCTR2021-002039-40-ES Germany;Italy;Korea, Republic of;Spain;United Kingdom;United States;
Novartis Pharma AG
2021 Phase 2 EUCTR2021-002039-40-DE Germany;Italy;Korea, Republic of;Spain;United Kingdom;United States;